Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Current Signal: SELL (auto-tracking)
0.57% $19.31
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 530.06 mill |
EPS: | -2.14 |
P/E: | -9.02 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 27.45 mill |
Avg Daily Volume: | 0.238 mill |
RATING 2024-04-19 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -9.02 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.48x |
Company: PE -9.02 | industry: PE 18.71 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 18.05 - 20.49 ( +/- 6.33%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-12 | Maetzold Derek J | Sell | 997 | Common Stock |
2024-04-12 | Maetzold Derek J | Sell | 997 | Common Stock |
2024-04-12 | Maetzold Derek J | Sell | 1 947 | Common Stock |
2024-04-12 | Maetzold Derek J | Sell | 318 | Common Stock |
2024-04-12 | Maetzold Derek J | Sell | 317 | Common Stock |
INSIDER POWER |
---|
32.18 |
Last 99 transactions |
Buy: 329 657 | Sell: 173 929 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $19.31 (0.57% ) |
Volume | 0.119 mill |
Avg. Vol. | 0.238 mill |
% of Avg. Vol | 50.04 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:32 | buy | $23.67 | N/A | Active |
---|
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.